MannKind's Uphill Climb to Partner Inhaled Insulin
This article was originally published in RPM Report
Executive Summary
MannKind no longer expects to land a partner for its inhaled insulin Afresa until FDA approval is in hand. Its not surprising that potential partners are skeptical given the regulatory and commercial challenges--but investors were disappointed nevertheless. Does MannKind know something other diabetes companies don't?
You may also be interested in...
The Year of the Unpartnered Blockbuster? High Profile Applications Raise Big Questions
Several of the highest profile new drug applications pending or expected to be submitted as 2010 begins involve potential blockbuster market opportunities. They also lack Big Pharma partners. Is Big Pharma really that picky? Or are the applications out of step with the regulatory and commercial climate? Either way, intense investor interest will keep FDA in the spotlight.
The New Oral MS Drugs: The Challenges in Dislodging Biologics
Oral replacements for injectable drugs have long been an industry aspiration. The complex issues riased by the first oral MS drugs, as they try to take over territory pioneered by large molecules, reveal the challenges for companies pursuing other biologic-dominated businesses.
The New Oral MS Drugs: The Challenges in Dislodging Biologics
Oral replacements for injectable drugs have long been an industry aspiration. The complex issues riased by the first oral MS drugs, as they try to take over territory pioneered by large molecules, reveal the challenges for companies pursuing other biologic-dominated businesses.